Miao Liu
Research Subjects
Miao Liu has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Somesh Nigam
Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA
2 shared publications B Mohundro
Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA
1 shared publicationB Vicidomina
Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA
1 shared publicationBenjamin V. Vicidomina
Blue Cross Blue Shield Louisiana, 5525 Reitz Ave, Baton Rouge, LA 70809 USA
1 shared publicationBrice L. Mohundro
Blue Cross Blue Shield Louisiana, 5525 Reitz Ave, Baton Rouge, LA 70809 USA
1 shared publicationD. Cantrell
Blue Cross Blue Shield of Louisiana, Baton Rouge, LA, USA
1 shared publication
Latest Publications
- 25 June 2022
- Published by Elsevier in Value in Health
- Vol. 25 (7) , S559
PCR98 The Continued Success of Value-Based Insurance Design (VBID): Blue Cross and Blue Shield of Louisiana's $0 Drug Co-Pay Program
- 25 June 2022
- Published by Elsevier in Value in Health
- Vol. 25 (7) , S559
PCR98 The Continued Success of Value-Based Insurance Design (VBID): Blue Cross and Blue Shield of Louisiana's $0 Drug Co-Pay Program
- 1 June 2020
- Published by Clinical Care Targeted Communications Group, LLC in The American Journal of Managed Care
- Vol. 26 (6) , e179-e183
Value-based insurance design in Louisiana: Blue Cross Blue Shield's Zero Dollar Co-pay program
Enrollment in a value-based insurance design program that eliminated pharmacy co-pays for 4 chronic disease drug classes was associated with a large decline in health care spending.
- 1 June 2020
- Published by Clinical Care Targeted Communications Group, LLC in The American Journal of Managed Care
- Vol. 26 (6) , e179-e183
Value-based insurance design in Louisiana: Blue Cross Blue Shield's Zero Dollar Co-pay program
Enrollment in a value-based insurance design program that eliminated pharmacy co-pays for 4 chronic disease drug classes was associated with a large decline in health care spending.
- Open Access
- 13 February 2020
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 23 (6) , 557-565
Evaluation of four disease management programs: evidence from blue cross blue shield of Louisiana
Aims: Chronic diseases impose a substantial healthcare burden. This study sought to evaluate the clinical and economic impact of new disease management (DM) programs, targeting 4 major chronic disease groups: diabetes, coronary heart disease (CHD)/hypertension (HTN), asthma/chronic obstructive pulmonary disease (COPD), and congestive heart failure (CHF)/chronic kidney disease (CKD). Materials and Methods: Between March 1, 2015, and February 28, 2018, members with Blue Cross Blue Shield of Louisiana insurance were contacted and enrolled in a DM program if they were aged 18 years through 64 years, eligible for a DM program, and had not been previously enrolled in a DM program. Active enrollees of a DM program (‘IN’ group) were compared to members who were not yet enrolled (‘OUT’ group). Average per member per month (PMPM) costs were aggregated annually to document any descriptive trends. Multivariable model estimates were used to compare PMPM costs for all IN subjects and all OUT subjects. Total medical savings were evaluated for the following time intervals: 1-12 months, 13-24 months, and 25-36 months. Results: For all 4 DM programs, average costs PMPM trended upward over time for the OUT cohort, while they remained relatively stable for the IN cohort. Some evidence also showed that DM programs improved clinical outcomes, such as hemoglobin A1c values. A difference in difference analysis showed PMPM savings for all 4 programs combined of $31.61, $50.45, and $53.72 after 1, 2, and 3 years, respectively. Multivariable modeling results showed total savings after 3 years of $14,460,174 for all DM programs combined. Limitations: Although multivariable models adjusted for several clinical, demographic, and economic characteristics; it is possible that some important confounders were missing due to lack of data. Conclusions: DM programs implemented to control diabetes, CHD/HTN, CHF/CKD, and asthma/COPD are cost-effective and show some evidence of improved clinical outcomes.
- 13 February 2020
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 23 (6) , 557-565
Open AccessEvaluation of four disease management programs: evidence from blue cross blue shield of Louisiana
Aims: Chronic diseases impose a substantial healthcare burden. This study sought to evaluate the clinical and economic impact of new disease management (DM) programs, targeting 4 major chronic disease groups: diabetes, coronary heart disease (CHD)/hypertension (HTN), asthma/chronic obstructive pulmonary disease (COPD), and congestive heart failure (CHF)/chronic kidney disease (CKD). Materials and Methods: Between March 1, 2015, and February 28, 2018, members with Blue Cross Blue Shield of Louisiana insurance were contacted and enrolled in a DM program if they were aged 18 years through 64 years, eligible for a DM program, and had not been previously enrolled in a DM program. Active enrollees of a DM program (‘IN’ group) were compared to members who were not yet enrolled (‘OUT’ group). Average per member per month (PMPM) costs were aggregated annually to document any descriptive trends. Multivariable model estimates were used to compare PMPM costs for all IN subjects and all OUT subjects. Total medical savings were evaluated for the following time intervals: 1-12 months, 13-24 months, and 25-36 months. Results: For all 4 DM programs, average costs PMPM trended upward over time for the OUT cohort, while they remained relatively stable for the IN cohort. Some evidence also showed that DM programs improved clinical outcomes, such as hemoglobin A1c values. A difference in difference analysis showed PMPM savings for all 4 programs combined of $31.61, $50.45, and $53.72 after 1, 2, and 3 years, respectively. Multivariable modeling results showed total savings after 3 years of $14,460,174 for all DM programs combined. Limitations: Although multivariable models adjusted for several clinical, demographic, and economic characteristics; it is possible that some important confounders were missing due to lack of data. Conclusions: DM programs implemented to control diabetes, CHD/HTN, CHF/CKD, and asthma/COPD are cost-effective and show some evidence of improved clinical outcomes.